DUBLIN--(BUSINESS WIRE)--The "2018 Systemic Mastocytosis Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Systemic Mastocytosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Systemic Mastocytosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered:
1 Systemic Mastocytosis Pipeline Analysis
2 Systemic Mastocytosis- Company Wise Pipeline Analysis
3 Systemic Mastocytosis R&D Pipeline Snapshots
4 Recent Developments in Systemic Mastocytosis Pipeline
- AB Science
- Allakos Inc
- Arog Pharmaceuticals
- Blueprint Medicines Corp
- Cosmo Pharmaceuticals NV
- Deciphera Pharmaceuticals
- KannaLife Sciences
- Mallinckrodt Pharmaceuticals
- Patara Pharma
- Rebiotix Inc
- Romark Laboratories
- Seattle Genetics Inc
- Stemline Therapeutics Inc
- Synlogic Inc
- Umecrine Cognition AB
For more information about this report visit https://www.researchandmarkets.com/research/p48dln/systemic?w=4